Working with TipRanks
Follow Us
Stock Ideas
Daily Updates
Calendars
Education
About Us
Working with TipRanks
Follow Us
Eagle Pharmaceuticals Inc (EGRX)
NASDAQ:EGRX
Eagle Pharmaceuticals (EGRX) Stock Price & Analysis
166 Followers
EGRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$18.02 - $47.71
Previous Close$18.3
Volume217.99K
Average Volume (3M)167.90K
Market Cap
$248.34M
Enterprise Value$302.77M
Total Cash (Recent Filing)$21.90M
Total Debt (Recent Filing)$76.33M
Price to Earnings (P/E)-83.8
Beta0.52
Next Earnings
Aug 08, 2023EPS Estimate
$0.99Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding13,091,344
10 Day Avg. Volume156,130
30 Day Avg. Volume167,897
Standard Deviation0.11
R-Squared0.20
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)4.10
Price to Sales (P/S)5.18
Price to Cash Flow (P/CF)1.90
P/FCF Ratio1.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.23
Enterprise Value/Gross Profit1.31
Enterprise Value/Ebitda8.24
Forecast
1Y Price Target
$29.50Price Target Upside56.50% Upside
Rating ConsensusHold
Number of Analyst Covering2
Eagle Pharmaceuticals News
Press ReleasesEagle Pharmaceuticals Reports First Quarter 2023 Results
Pre-EarningsEGRX Earnings this Week: How Will it Perform?
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EGRX FAQ
What was Eagle Pharmaceuticals Inc’s price range in the past 12 months?
Eagle Pharmaceuticals Inc lowest stock price was $18.02 and its highest was $47.71 in the past 12 months.
What is Eagle Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Eagle Pharmaceuticals Inc’s upcoming earnings report date?
Eagle Pharmaceuticals Inc’s upcoming earnings report date is Aug 08, 2023 which is in 61 days.
How were Eagle Pharmaceuticals Inc’s earnings last quarter?
Eagle Pharmaceuticals Inc released its earnings results on May 09, 2023. The company reported $1.26 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.21.
Is Eagle Pharmaceuticals Inc overvalued?
According to Wall Street analysts Eagle Pharmaceuticals Inc’s price is currently Undervalued.
Does Eagle Pharmaceuticals Inc pay dividends?
Eagle Pharmaceuticals Inc does not currently pay dividends.
What is Eagle Pharmaceuticals Inc’s EPS estimate?
Eagle Pharmaceuticals Inc’s EPS estimate is $0.99.
How many shares outstanding does Eagle Pharmaceuticals Inc have?
Eagle Pharmaceuticals Inc has 13,091,344 shares outstanding.
What happened to Eagle Pharmaceuticals Inc’s price movement after its last earnings report?
Eagle Pharmaceuticals Inc reported an EPS of $1.26 in its last earnings report, beating expectations of $1.05. Following the earnings report the stock price went down -13.301%.
Which hedge fund is a major shareholder of Eagle Pharmaceuticals Inc?
Among the largest hedge funds holding Eagle Pharmaceuticals Inc’s share is Brandes Investment Partners LP. It holds Eagle Pharmaceuticals Inc’s shares valued at 15M.
---
Eagle Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$29.50 (56.50% Upside)
$29.50 (56.50% Upside)
Blogger Sentiment
Bullish
EGRX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 159.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.04%
12-Months-Change
Fundamentals
Return on Equity
-1.16%
Trailing 12-Months
Asset Growth
29.36%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Eagle Pharmaceuticals Inc
Eagle Pharmaceuticals, Inc. engages in the provision of injectable products. Its products include argatroban, ryanodex, docetaxel injection, non-alcohol formulation and bendeka. The company was founded by Scott L. Tarriff on January 2, 2007 and is headquartered in Woodcliff Lake, NJ.
---
Top 5 ETFs holding EGRX
Vanguard Health Care ETF
$1.16M
Fidelity MSCI Health Care Index ETF
$122.17K
iShares NASDAQ US Biotechnology UCITS ETF
$114.71K
SPDR Portfolio S&P 1500 Composite Stock Market ETF
$54.82K
Up to five ETFs with an Outperform Smart Score that hold EGRX. The ETFs are listed according to market value of EGRX within the ETF
---
Pacira Pharmaceuticals
―
Spectrum Pharmaceuticals
―
Karyopharm Therapeutics
―
SAGE Therapeutics
―
---